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Abstract
Purpose: To analyze the role and translational potential for hypermethylation of CpG islands and shores
in the regulation of small RNAs within urothelial cell carcinoma (UCC). To examinemicroRNAs (miR) and
mirtrons, a new class of RNA located within gene introns and processed in a Drosha-independent manner.
Experimental design: Themethylation status of 865 small RNAswas evaluated in normal andmalignant
cell lines by using 5-azacytidine and microarrays. Bisulfite sequencing was used for CpG regions around
selected RNAs. Prognostic and diagnostic associations for epigenetically regulated RNAs were examined by
usingmaterial from359 patients, including 216 tumors and121 urinary samples (68 cases and 53 controls).
Functional analyses examined the effect of silencing susceptible RNAs in normal urothelial cells.
Results: Exonic/UTR-located miRs and mirtons are most susceptible to epigenetic regulation. We
identified 4 mirtrons and 16 miRs with CpG hypermethylation across 35 regions in normal and malignant
urothelium. For several miRs, hypermethylation was more frequent and dense in CpG shores than islands
(e.g., miRs-9/149/210/212/328/503/1224/1227/1229), and was associated with tumor grade, stage, and
prognosis (e.g., miR-1224 multivariate analysis OR ¼ 2.5; 95% CI, 1.3–5.0; P ¼ 0.006). The urinary
expression of epigenetically silenced RNAs (miRs-152/328/1224) was associated with the presence of UCC
(concordance index, 0.86; 95% CI, 0.80–0.93; ANOVA P < 0.016).
Conclusions:Hypermethylation ofmirtrons andmiRs is common in UCC.Mirtrons appear particularly
susceptible to epigenetic regulation. Aberrant hypermethylation of small RNAs is associated with
the presence and behavior of UCC, suggesting potential roles as diagnostic and prognostic biomarkers.
Clin Cancer Res; 17(6); 1287–96. 2010 AACR.
Introduction
Urothelial cell carcinoma (UCC) of the bladder is the
fourth commonest male malignancy, third most prevalent
and one of the most expensive cancers in the United States
(1). Most UCC are low-grade tumors that are characterized
by mutations of FGFR3 and relative genetic and epigenetic
stability. These tumors frequently recur within the bladder,
but rarely progress to invasion. High-grade UCC have
numerous genetic events and are characterized by loss of
the p53 function (2, 3). These tumors may be diagnosed
while confined within the urothelium, but frequently pro-
gress to muscle invasion. High-grade tumors have frequent
CpG island hypermethylation and this can be used to
identify progression risk (4, 5).
MicroRNAs (miR) are short noncoding RNAs that post-
transcriptionally regulate gene expression and are impli-
cated in carcinogenesis (6). We have recently observed
differential expression of numerous miRs in malignant
and normal urothelium (7). These alterations may arise
from either genetic or epigenetic events (6, 8). Although it
is known that CpG island hypermethylation is associated
with tumor-suppressor gene silencing, this alteration is not
always disease specific (9). Epigenome-wide profiling has
revealed that many regions with cancer-specific differential
methylation are located adjacent to CpG islands in regions
of less dense CpG dinucleotides, termed CpG shores (10).
Hypermethylation of these shores appears important in the
regulation of gene expression.
Little is known about epigenetic control of miR expres-
sion in UCC. Reports in other malignancies have found
aberrant CpG island hypermethylation is associated with
miR silencing (11–13). We hypothesized that altered miR
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expression in UCC may arise from epigenetic mechanisms
and that changes occur in both CpG islands and shores. We
were also interested in a new class of small RNA, termed
mirtrons (14, 15). These are transcribed from short introns
and processed independently of Drosha. We hypothesized
their location within gene coding RNAs may make them
susceptible to epigenetic silencing. To test these hypotheses
we examined the methyl status of 700 small RNAs and
mapped their proximity to both CpG islands and differ-
entially methylated shore regions.
Materials and Methods
Patients and samples
We investigated 359 patient samples and 4 urothelial cell
lines representing low-grade (RT4), high-grade (RT112),
and invasive (EJ/T24) UCC, and normal human urothe-
lium (NHU; ref. 7, 16). To explore the frequency and
translational roles for epigenetic miR silencing we studied
malignant and normal urothelial tissues from 238 patients
(Table 1) and 121 freshly voided urinary samples (cohort 3,
Table 1; detailed in Miah and colleagues, submitted manu-
script). Urinary controls included those without disease,
those with symptoms suggestive of UCC, urinary stones,
and benign prostatic enlargement. Patients with hematuria
or uropathology had UCC excluded by cystoscopy and
urinary tract imaging (n ¼ 50/53, 94%). Ethics committee
approval was obtained prior to opening this study and
patients recruited following informed consent.
RNA expression and methylation of CpG
dinucleotides and adjacent histones
To determine CpG hypermethylation we compared miR
and mirtron expression in cell lines using microarrays
before and after DNA methyltransferase inhibition with
5-azacytdine. To determine methylation of individual cyto-
sines we used bisulfite sequencing of CpG regions adjacent
to miRs (methods detailed in Supplementary Material and
ref. 17). We used commercial microarrays containing
probes to 865 human small RNAs (V2 miRNA microarray;
Agilent; GEO Platform: GPL7731) in triplicate for each cell
line and treatment. Expression of individual miRs was
measured by real-time RTPCR (Applied Biosystems) as
previously described (7). For DNA methyltransferase inhi-
bition we grew cells for 5 to 7 days in 2 mmol/L 5-azacy-
tidine (Sigma).
We selected RNAs for analysis by using bisulfite sequen-
cing from those in which 5-azacytdine induced altered
expression and were adjacent to CpG islands and differ-
entially methylated regions (DMR), frommiRs found to be
methylated in other tumors, and from RNAs located adja-
cent to both CpG islands and DMRs (12, 13, 18). Briefly,
target CpG regions were amplified by using bisulfite-spe-
cific PCR, the products cleaned and cloned into Escherichia
coli before sequencing (detailed in ref. 19). Histone mod-
ification adjacent to CpG regions was determined by chro-
matin immunoprecipitation with antibodies to histone-3
lysine-9 trimethylation (Millipore) and a nonspecific con-
trol (rabbit IgG; Santa Cruz Biotechnology).
Methylation in primary tumors and phenotypic effects
Clinicopathologic associations with methylation were
examined in 176 microdissected samples by using
methyl-specific PCR (Supplementary Methods; Supple-
mentary Table 1). Products were visualized in a 3% agarose
gel and compared with positive (universally methylated
DNA; Invitrogen) and negative controls (4). The regulation
of cell proliferation by RNAs susceptible to epigenetic
silencing was evaluated by the MTT assay. Six replicates
for each experiment were conducted in NHU cells reverse
transfected with specific anti-miR molecules (50 nmol/L;
Ambion) and a scrambled RNA sequence (negative con-
trol). Cells were transfected once by using siPORT NeoFX
reagent at the start of the experiment (as detailed in ref. 7).
Successful knockdown was confirmed with QRTPCR.
Bioinformatics and statistical analyses
To examine CpG proximity and to annotate our micro-
array we combined the location of all small RNAs on our
microarray (n¼ 865), all human CpG islands (n¼ 28,227)
more than 200 bp in length (20), and the 19,086 DMRs
recently identified (10)—of which 73%were CpG shores—
into a single database. We incorporated the miRGen data-
base describing the relationship with coding genes for 443
miRs (21). We carried out a similar analysis for 36,953
coding genes.
RNA expression was compared between treated and
untreated matching cell lines by microarray fluorescence
values extracted by using feature selection software (Agi-
lent). We compared CpG methylation and RNA expression
with clinicopathologic features by c2 or Kendall-tau test for
discrete variables, ANOVA or Mann–Whitney U test for
continuous data, and the log-rank test with Kaplan–Meier
plots for outcome. Tumor progression was defined as
pathologic, radiological, or clinical evidence of an increase
in tumor stage and measured from the time of surgery.
Individual miR expression was determined by real-time
Translational Relevance
Altered microRNA (miR) expression is common in
urothelial cell carcinoma (UCC) and reflects genetic
events within tumors. Here we identify a cohort of miRs
and mirtons, a new class of small RNAs, which are
susceptible to epigenetic silencing. We show DNA
hypermethylation in 35 CpG regions adjacent to 20
miRs. We find miRs-152/1224 have prognostic and
diagnostic value in UCC. We show hypermethylation
of CpG shore regions and find it more common and
potentially disease specific than corresponding CpG
islands. Finally we identify that mirtrons are particularly
susceptible to epigenetic silencing in cancer. These data
reveal insights into disease biology and suggest epigen-
etically silenced small RNAs are potential therapeutic
targets and could be used as biomarkers in UCC.
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PCR and quantified relative to RNU48 (DCt ¼ CtmiR 
CtRNU48). All statistical analyses were 2-sided and con-
ducted in SPSS (Vsn. 14.0 SPSS Inc.; ILL) by using P <
0.05 for significance.
Results
MicroRNA genes, mirtrons, coding genes, and CpG
proximity
We were able to map 705 small RNAs to CpG island and
DMR proximity. We found 155 (22%) and 263 (37%) of
these were located within 3 and 10 kb of a CpG island,
respectively (Supplementary Fig. 1; http://www.shef.ac.uk/
medicine/oncology/units/urology/data.html). This distri-
bution is similar to that for coding RNA genes [n ¼
7,494 (25%) and n ¼ 12,409 (42%), respectively, c2P >
0.05]. For DMRs, we found 90 (13%) and 168 (24%) miRs
were located within 3 and 10 kb, respectively. MiRs closest
to DMRsweremore often those within 3 kb of a CpG island
[59 of 155 (38%)] than those distant [31 of 550 (11%), c2P
< 0.0001]. We located protein coding gene proximity for
443 miRs and found 254 (57%) were intergenic, and 189
(43%) intragenic [including 151 (34%) intronic]. MiRs
located within coding gene exons and UTRs were closer to
CpG islands and DMRs [n ¼ 16–23 of 36 (44%–64%)
within 10 kb] than those within introns [n¼ 33—50 of 151
(22–33%)] and intergenic regions [n ¼ 67–94 of 254 (26–
37%), c2P ¼ 0.002). In total, 15 of 38 (40%) exonic and
UTR miRs were close to both CpG structures. We mapped
13 of 19 known mirtrons to chromosomal location (22).
The majority were close to CpG islands [<10 kb, n¼ 9 of 13
(69%)], but only 3 of 13 (23%) were near a DMR. Thus
Table 1. Details of the tumors and cases studied in this report
Cohort 1 UCC cases Cohort 2 UCC cases Cohort 3
UCC cases Control cases
Grade
Grade 1 11 (21) 30 (18) 15 (22)
Grade 2 12 (23) 70 (43) 21 (31)
Grade 3 29 (56) 63 (38) 32 (47)
NK 0 (0) 1 (1) 0 (0)
Stage
pTa 25 (48) 60 (37) 33 (49)
pT1 9 (17) 30 (18) 8 (12)
pT2–4 18 (35) 73 (45) 27 (40)
NK 0 (0) 1 (1) 0 (0)
Tumor phenotype
Low-grade NMI 22 (42) 51 (31) 30 (44)
High-grade NMI 12 (23) 38 (23) 11 (16)
Invasive 18 (35) 74 (45) 27 (40)
NK 0 (0) 1 (1) 0 (0)
Progression
No 34 (65) 101 (62) NA
Yes 18 (35) 61 (37) NA
NK 0 (0) 2 (1) NA
Median follow-up, mo NA
No progression 54 37 NA NA
Until progression 10 14 NA NA
Control diagnosis
Prostatectomy 8 12
Hematuria 28 (53)
Stone disease 10 (19)
Urosepsis 6 (11)
BPH (TURP) 2 6 (11)
Othera 3 (6)
Total 62 176 68 53
NOTE: All values are given as n (%), unless mentioned otherwise.
Abbreviations: NA, not applicable; NK, not known.
aVarious controls including circumcision (1), pulmonary embolus (1), appendicitis (1).
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mirtrons and exonic/UTR-located miRs are potentially
most susceptible to epigenetic silencing.
MicroRNA and mirtrons expression following
5-azacytidine
Microarrays detected the expression of 465 RNAs from
the 865 examined (deposited data: GEO GSE22380). Indi-
vidual RTPCR measurements by TaqMan Low-Density
Airways (TLDA) RTPCR arrays confirmed microarray
quantification (Pearson’s correlation r ¼ 0.65 to
0.74, P < 1017; ref. 7). For each cell line we calculated
the change in RNA expression following 5-azacytidine
treatment (Supplementary Table 2). Hierarchical clustering
revealed cell lines grouped according to identity rather than
5-azacytidine treatment (Supplementary Fig. 2). In total,
195miRs increased and 73 decreased the frequency of their
expression with 5-azacytidine. MiRs with altered expression
were not related to CpG/DMR/coding gene proximity
(Kendall-tau test, P > 0.2). Of the 268 miRs with altered
expression, 75 (28%) and 124 (46%) were within 3 and 10
kb of a CpG island, and 41(15%) and 86 (32%)within 3 kb
and 10 kb of a DMR. In total, 27 (11%) and 79 (29%)miRs
were within 3 kb and 10 kb of both a CpG regions. To
determine the relationship between expression and DNA
methylation we selected 20 miRs for analysis from those
with altered expression after 5-azacytidine that were close
to CpG islands and DMRs, and mostly expressed in NHU
cells (Supplementary Table 2). We included miRs-9/34b/
152 as they have previously been reported aberrantly
hypermethylated in cancer and a sample of those close
to both DMRs and CpG islands (12, 13).
Methyl status of CpG islands and DMRs
Bisulfite sequencing revealed hypermethylation of many
CpG islands and DMRs (Table 2; Fig. 1A). For RNAs
adjacent to only CpG islands, we usually found hyper-
methylation in one or more cell line. For miRs-9–3/152/
516a/551a hypermethylation appeared tumor-specific. In
miRs close to both CpG islands and DMRs, we saw 2
patterns of methylation. For most (9 of 13 RNAs) we found
the DMR had more extensive and was more frequently
hypermethylated than the corresponding island. For the
remaining RNAs (4 of 13) there was equal hypermethyla-
tion of both regions. In 3 RNAs (miR-210/212/1227) the
difference in hypermethylation between DMR and CpG
island was absolute.
To compare RNA expression and DNA methylation
directly, we measured these for miR-1224 in EJ before
and after 5-azacytdine (Supplementary Fig. 3). We chose
this cell line as its showed absolute hypermethylation with
sequencing (Fig. 1) and miR upregulation by using micro-
arrays. We found that 5-azacytidine reduced DNAmethyla-
tion levels in both the CpG island and shore (mean 1.0 to
mean 0.46) and this was associated with a 4-fold increase
in miR-1224-3p expression [mean DDCt 4.21 (Nb. miR-
1224-3p is the dominant species from the miR-1224
gene)]. We then compared methylation and expression
in 20 UCC cases from cohort 1. Once again we found
the presence of hypermethylation was significantly asso-
ciated with low RNA expression (ANOVA P < 0.006; Sup-
plementary Fig. 3D).
We expected methyl patterns to be disease specific, but
detected CpG hypermethylation in NHU cells. As NHU
cells are adapted to in vitro growth and fail to grow in the
presence of 5-azacytidine, they may have acquired epige-
netic alterations in their transition from NHU (23). We
performed bisulfite sequencing on 18 CpG islands and
DMRs in corresponding pairs of frozen urothelial biopsies
(taken at harvesting) and culture-adapted NHU cells (Sup-
plementary Table 3). For most loci the paired samples had
identical methyl profiles. For miR-149 there were 2 pairs in
which the NHU cells were enriched for hypermethylation,
when compared with the frozen counterparts (samples #2,
#3, Supplementary Fig. 4).
Histone methylation adjacent to CpG islands and
DMRs
Histone-3 lysine-9 trimethylation is associated with
hypermethylation of the adjacent DNA. To date, most
investigators have described this association in CpG
islands. We were interested to see whether the association
persisted in the less dense DMR regions (i.e., CpG shores).
Using chromatin immunoprecipitation and PCR we
detected this modification in both CpG islands and DMRs.
Histone methylation often matched the corresponding
DNA methyl status (Fig. 1B; densitometry in Supplemen-
tary Fig. 5). For example, the CpG islands around miRs-
149/212 are unmethylated at the DNA and for histone-3
lysine-9, in contrast to the adjacent DMR.
Cell phenotype and RNA expression
We previously profiled the expression of 365 miRs in 52
UCC (cohort 1; ref. 7; data deposited: http://www.shef.ac.
uk/medicine/oncology/units/urology/data.html). We ana-
lyzed progression-free survival in these 52 patients by using
13 of the 20 identified miRs (Nb. 7 miRs not present on the
TLDA array). Normalized miR expression was dichoto-
mized around themean and normal expression determined
from10normal urothelial samples (patientswithoutUCC).
We detected higher progression rates with reduced expres-
sion for miRs-152/193a/503 (log-rank P < 0.05; Supple-
mentary Fig. 6) and nonsignificant trends toward higher
progression rates with reduced expression for miRs-9/24/
126/34a/210 (P < 0.2), compared with tumors with normal
expression. The low sample size may have prevented suffi-
cient analysis of these loci. Multivariate analysis using
clinicopathologic details and miR-152/193a/503 expres-
sion revealed that stage (Cox OR ¼ 2.0; 95% CI, 1.1–3.7)
and miR-152 expression (Cox OR ¼ 0.8; 95% CI, 0.7–0.9)
were the factors most associated with progression.
We chose miR-152 and miR-1224 for further analysis.
MiR-1224 was absent on the TLDA array but appeared
differentially methylated in the urothelium and across the
island/shore regions. To examine a functional role for
these we measured proliferation following miR knock-
down. MTT assays in NHU cells with loss of miR-152
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and miR-1224 revealed generally higher proliferation rates
when compared with control cells. This reached signifi-
cance at 14 days (Supplementary Fig. 7A; ANOVA P <
0.001). Quantification of miR knockdown revealed that
RNA expression returned to pretreatment levels by day 5
(Supplementary Fig. 7B), suggesting that the mRNA
changes affecting proliferation occur within the first 5 days
and are not dependant on continuous miR suppression.
Mirtron and microRNA hypermethylation in bladder
tumors
Hypermethylation at the CpG island and DMR adjacent
to miR-1224 and the CpG island for miR-152 was analyzed
by using DNA from cohort 2. Bisulfite conversion was
determined by using primers to the unmethylated CpG
islands (Fig. 2). For each locus, hypermethylation was
significantly more common in malignant than NHU
Table 2.Methyl status of CpG islands and shores (DMRs) adjacent to selected miR genes for those close
to islands only and both features
miRNA CpG
feature
Gene
proximity (bp)
CpG
dinucleotides
sequenced
Average methylationa CpG statusb
EJ RT112 RT4 NHU EJ RT112 RT4 NHU
CpG islands only
miR-9-3 Island 726 20 1.0 1.0 0.6 0.0 M M M U
miR-34a Island 23,223 22 1.0 1.0 1.0 1.0 M M M M
miR-126 Island 54 13 0.8 0.8 0.8 0.8 M M M M
miR-152 Island 47 9 1.0 1.0 1.0 0.2 M M M U
miR-200b* Island 4,440 9 1.0 1.0 1.0 1.0 M M M M
miR-516a Island 7,354 12 0.0 1.0 1.0 0.0 U M M U
miR-551a Island 17,384 7 0.0 1.0 1.0 0.0 U M M U
miR-744 Island 61,264 12 0.0 0.0 0.0 0.0 U U U U
miR-1226* Island 85 13 0.8 1.0 0.8 1.0 M M M M
CpG islands and shores
miR-9-1 Island 271 19 1.0 1.0 0.6 0.0 M M M U
Shore 704 4 1.0 1.0 1.0 0.8 M M M M
miR-9-2 Island 5,965 6 1.0 1.0 0.0 0.0 M M U U
Shore 210 3 1.0 0.6 1.0 1.0 M M M M
miR-24-1* Island 162 14 1.0 1.0 1.0 0.8 M M M M
Shore 5,604 2 1.0 0.8 1.0 1.0 M M M M
miR-34b Island 494 9 1.0 1.0 1.0 0.6 M M M M
Shore 1,099 4 1.0 1.0 1.0 1.0 M M M M
miR-149 Island 169 15 0.6 0.0 0.0 0.0 M U U U
Shore 1,129 4 1.0 1.0 1.0 1.0 M M M M
miR-193a Island 1,107 24 1.0 1.0 1.0 0.8 M M M M
Shore 29 5 1.0 1.0 0.8 0.6 M M M M
miR-210 Island 150 12 0.0 0.0 0.0 0.0 U U U U
Shore 8,509 4 1.0 1.0 1.0 1.0 M M M M
miR-212 Island 645 9 0.0 0.0 0.0 0.0 U U U U
Shore 6,722 3 1.0 1.0 1.0 0.8 M M M M
miR-328 Island 3,191 9 1.0 1.0 1.0 0.0 M M M U
Shore 4,405 4 1.0 0.8 1.0 0.6 M M M M
miR-503 Island 109 7 0.0 0.8 0.0 0.0 U M U U
Shore 251 4 1.0 1.0 0.8 0.8 M M M M
miR-1224 Island 134 10 1.0 0.6 0.6 0.2 M M M U
Shore 9,596 4 1.0 1.0 1.0 0.0 M M M U
miR-1227 Island 1,621 11 0.0 0.0 0.0 0.0 U U U U
Shore 6,335 7 1.0 1.0 1.0 1.0 M M M M
miR-1229 Island 545 11 0.8 0.0 0.0 0.0 M U U U
Shore 4,556 5 0.2 0.6 0.6 0.6 U M M M
aAverage percentage of methylation for each cytosine residue (calculated from 5 E. coli clones).
bM, methylated (>20% of clones were methylated); U, unmethylated (20% of clones had methylated alleles).
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(c2P < 0.032; Table 3). The extent of methylation increased
with worsening differentiation and advancing stage. This
increase reached statistical significance for all relationships
except miR-1224 CpG island and tumor grade (c2P ¼
0.43). When compared, hypermethylation at the DMR
for miR-1224 appeared pathologically more specific than
for the island (Table 3). For each locus there was more
progression to advanced disease in tumors with miR hyper-
methylation, than those without this change (log-rank P <
0.003, Fig. 2B). The DMR (CpG shore) at miR-1224
appeared more predictive than the CpG island. Multivari-
ate analysis including clinicopathologic details revealed
that miR-1224 DMR hypermethylation (Cox OR ¼ 2.5;
95%CI, 1.3–5.0; P¼ 0.006), grade (CoxOR¼ 1.7; 95%CI,
1.1–2.7; P¼ 0.012), and stage (CoxOR¼ 1.6; 95%CI, 1.1–
2.3; P ¼ 0.007) were independently associated with tumor
progression. Concordant methylation of the DMR and
island at miR-1224 was found in 104 of 153 (68%) tumors
(r ¼ 0.34, P < 0.0001).
Urinary mirtron and microRNA expression
We compared the expression of epigentically regulated
RNAs in cells from 121 urine samples (68 UCC cases and
53 controls). We measured the expression by using com-
mercial assays and normalized to RNU48 (methods
detailed in Miah and colleagues, submitted manuscript).
Figure 1. Methylation of cytosine
residues and adjacent histones in
CpG islands and shores in bladder
cancer. A, bisulfite sequencing
reveals the methylation status of
CpG islands and shores adjacent
to 5 miRs in each cell line.
Methylation at individual cytosines
is illustrated as a percentage from
5 cloned products. The CpG
island (has more CpG
dinucleotides and so appears
larger than the shore) is closer to
the gene start site than the shore
for all illustrated miRs except miR-
193a. B, chromatin
immunoprecipitation PCR
agarose images (displayed
cropped for clarity) reveal the
presence of trimethylated histone-
3 lysine-9 for various CpG islands
and shores. For each target PCR
the input DNA (i.e., sonicated DNA
removed prior to
immunoprecipitation) is shown
next to the DNA precipitated with
an antibody to H3K9-3m and a
nonspecific control (rabbit IgG
antibody).
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We analyzed miRs-152/212/328 and miR-1224-3p, and
found each was detected more frequently and with a higher
expression in urinary samples from cancer-free controls
than in patients with UCC (ANOVA P < 0.016; Table 4;
Fig. 2C). Low expression of miRs-152/328/1224 were most
diagnostic of UCC (concordance indices, 0.80–0.84). We
dichotomized each RNA around its mean and scored
samples according to the number of abnormally expressed
RNAs. The combination of low miRs-152/328/1224-3p
was most concordant with UCC (Concordan index,
0.86; 95% CI 0.80–0.93; Fig. 2D).
Discussion
Approximately one third of miRs are close to CpG
islands, approximately one fourth are close to CpG shores,
and approximately one fifth are close to both structures.
The likelihood of proximity to these regions increases to
approximately half for miRs located within coding gene
exons and UTRs, and further still for mirtrons (70% are
close to CpG islands). Our systematic analysis has revealed
the clustering found for many miRs creates potential hot-
spots of epigenetic deregulation where CpGmethylation at
single locus may affect numerous miRs. For example, we
identified hypermethylation of the CpG shore and island at
miR-24-1. This miR is clustered withmiR-23b andmiR-27b
around this CpG island on Chr 9q22.32 within the 30UTR
of Aminopeptidase O and upstream of FANCC. Loss of
9q22 occurs in 50%of UCC (24) and targets include PTCH,
TGFBR1, TSC1, and DBCCR1. MiR-24 is known to have a
p53-independent antiproliferative effect (25). We pre-
viously observed correlated downregulation of these 3
Figure 2. Prognostic and
diagnostic roles for small RNAs
with CpG island and shore
methylation. A, examples of tumor
analysis for CpG methylation
(Meth) by using methyl-specific
PCR. Successful bisulfite
conversion and DNA integrity
were confirmed by using primers
specific to bisulfite treated
unmethylated (Unmeth) DNA
(those for unmethylated miR-152
shown here). Eight representative
tumors are shown. B,
progression-free survival in
bladder cancer according to miR
methylation. Progression to more
advances stage was more in
samples with hypermethylation of
the CpG island and shore adjacent
to miR-1224 and the island next to
miR-152 (log-rank P values
shown). C, urinary mirtron andmiR
expression in patients with
bladder cancer and age matched
controls. Low expression of all 4
miRs was associated with the
presence of UCC. DCt values are
plotted and expression is
significantly less for each miR in
UCC cases, when compared with
controls. D, receiver–operator
curves reveal the diagnostic
performance of each miR and the
combination of miRs-152/328/
1224-3p (area under curve shown
in brackets).
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miRs inUCC (Supplementary Fig. 8A). There are other such
potential epigenetic hotspots, including the 6 miRs around
within C13orf25 at 13q31.3 (correlated expression illu-
strated in Supplementary Fig. 8B), miRs-16–2/15b within
SMC4 at 3q26, miRs-647/1914 with UCKL1 at 20q13.33,
and miRs-449a/449b within CDC20 at 5q11.
Our experiments focused on CpG methylation around
small RNAs and identified a high frequency of DNA
hypermethylation among selected small RNAs. We con-
firmed reports of aberrant hypermethylation in other
tumors for miRs-34a/126/149/152/193a/200b/210/
212/503/516a and for miRs-9-1/9-2/9-3 (26, 27). We
identified new miRs susceptible to epigenetic silencing
including miRs-24-1/328/551a and mirtrons miRs-
1224/1226/1227/1229. These data are interesting as they
reveal that epigenetic silencingmay be generic to cancer or
subtype specific. Hypermethylation of miRs-9/34/200 has
been reported in UCC, colon, breast, lung, and kidney
cancers (12, 26–28), suggesting they control events generic
tomalignancy. Indeed the combination ofmiR-9 andmiR-
Table 3. Aberrant hypermethylation of the CpG islands adjacent to miR-152 and miR-1224 and urothelial
cancer
miR-152, n (%) miR-1224CpGShore,n (%) miR-1224CpG Island, n (%)
Unmethylated Methylated c2P Unmethylated Methylated c2P Unmethylated Methylated c2P
Tissue
Normal 10 (83.3) 2 (16.7) 9 (75.0) 3 (25.0) 8 (66.7) 4 (33.3)
Malignant 80 (50.6) 78 (49.4) 0.029 64 (40.5) 94 (59.5) 0.02 52 (35.4) 95 (64.6) 0.032
Grade
Grade 1 20 (12.7) 10 (6.4) 18 (11.5) 12 (7.6) 12 (7.6) 14 (8.9)
Grade 2 36 (22.9) 32 (20.4) 32 (20.4) 36 (22.9) 22 (14.0) 41 (26.1)
Grade 3 23 (14.6) 36 (22.9) 0.04 14 (8.9) 45 (28.7) 0.002 18 (11.5) 39 (24.8) 0.43
Stage
pTa 46 (29.3) 14 (8.9) 34 (21.7) 26 (16.6) 29 (18.5) 24 (15.3)
pT1 15 (9.6) 14 (8.9) 13 (8.3) 16 (10.2) 8 (5.1) 20 (12.7)
pT2–4 18 (11.5) 50 (31.8) <0.001 17 (10.8) 51 (32.5) 0.001 15 (9.6) 50 (31.8) 0.001
Phenotype
Low-grade NMI 39 (24.8) 12 (7.6) 32 (20.4) 19 (12.1) 26 (16.6) 18 (11.5)
High-grade NMI 21 (13.4) 16 (10.2) 15 (9.6) 22 (14.0) 11 (7.0) 25 (15.9)
Invasive 19 (12.1) 50 (31.8) <0.001 17 (10.8) 52 (33.1) <0.001 15 (9.6) 51 (32.5) <0.001
Missing 7 (4.3) 7 (4.3) 18 (11)
Table 4. Urinary RNA expression and the diagnosis of bladder cancer
miR-152 miR-212 miR-328 miR-1224–3p Combination
of miRs-152/
328/1224-3p
Benign
Detected, n (%) 51 (96) 50 (94) 53 (100) 51 (96)
Expression, DCt mean (SD) 16.4 (8.4) 12.4 (5.8) 10.6 (3.5) 15.2 (3.7)
UCC
Detected, n (%) 24 (35) 59 (87) 56 (82) 58 (85)
Expression, DCt mean (SD) 31.9 (11.3)a 14.9 (5.2) 18.2 (8.0) 20.7 (5.7)
Difference
Fold change in UCC 0.00002a 0.17 0.01 0.02
ANOVA P <0.0001a 0.016 <0.0001 <0.0001
Diagnostic performance
Sensitivity 0.88 0.40 0.59 0.84 0.81
Specificity 0.58 0.66 0.91 0.58 0.75
Concordance with UCC (95% CI) 0.84 (0.77–0.91) 0.66 (0.57–0.76) 0.84 (0.77–0.91) 0.80 (0.72–0.89) 0.86 (0.80–0.93)
aCorrected for absent results.
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200 has recently been proposed as prognostic signature for
cervical cancer (29). In contrast, hypermethylation for
miRs-24-1/126/212 appears specific to UCC and colon
cancer (12), as this does not occur in other tumors (27).
No previous reports have identified hypermethylation of
miRs-328/551a/1224/1226/1227/1229 in cancer. This
may be due to disease specificity (possibly for miR-328/
551a) or that these targets were not analyzed previously.
MiRs-1224/1226/1227/1229 belong to a recently identi-
fied family of small RNAs known asmirtons (14, 15). These
differ frommiRs in their genomic structure and processing.
Mirtron genes are transcribed as hairpins, spliced, and
debranched in a Drosha-independent manner (30). Their
genomic structure consists of short introns that use splicing
to avoid Drosha cleavage. Following nuclear export, mir-
trons are integrated into the canonical miR pathway and
cleaved by Dicer before incorporation into the RNA-silen-
cing complex (14, 15).Mirtronhairpins preferentially select
the 30 transcript for mRNA targeting, in contrast to the 50
predominance for miRs. Each mirtron is located within a
coding gene intron (Table 2) making them interesting from
the genomic perspective and often located close to CpG
islands. Themirtronswe identified are foundwithin regions
implicated in human cancer and in UCC specifically. MiR-
1224 is located at 3q27.1within aCpG island in intron18of
VWA5B2 (von Willebrand factor A domain containing
5B2). This is close to the p63 tumor suppressor gene that
is downregulated and associated with a poor prognosis in
UCC (31). MiR-1226 is within the putative RNA helicase
DHX30 at 3p21.1, a fragile site deleted in lung and other
tumors (32, 33). Deletion of this region is associated with
smoking andasbestos exposure suggestingdirect carcinogen
targeting (34). MiR-1227 is located at 19p13.3, close to
STK11 the gene implicated in Peutz–Jeghers syndrome, and
within a region deleted in colon cancer (35). MiR-1229 is
found within a glycotransferase (MGAT4B) at 5q35.5. This
region is deleted in a small fractionofUCCbut is a common
fragile site in lung cancer (33, 36). Epigenetic silencing of
MGAT4B is likely in cancer as down regulation occurs
during the development of drug resistance (37) and can
be reversed by 5-azacytidine (38). Interestingly, compara-
tive genomic hybridization analysis of lung tumors identi-
fied 3 of our 4mirtron loci and that for miR-1225, as fragile
hotspots deleted within the disease (33).
We selected miR-152 and miR-1224 for prognostic and
diagnostic evaluation. The expression of both was asso-
ciated with the presence and phenotype of UCC. This
suggests they play roles in urothelial carcinogenesis and
the need for functional studies to evaluate mRNA targets.
When compared it appeared that methylation of the CpG
shore for miR-1224 was more prognostic and more closely
associated with phenotype than for the island. This sup-
ported cell line observations, where CpG shoremethylation
was more common and extensive than for islands. This was
especially true for mirtrons. These observations support the
role for CpG shore hypermethylation in human cancer and
could potentially lead to more disease-specific diagnostic
tests. Studies of CpG island hypermethylation around
tumor suppressor genes report age related changes that
affect diagnostic test specificity (9). It should be noted that
conflicting observations were seen with respect to cancer
specificity andCpG island and shoremethylation. Although
for miR-1224 the shore appeared more cancer specific than
the island, the reverse was true for miR-9-1/-2. Further
studies to evaluated CpG shore regions are needed in UCC.
In conclusion, we have identified a cohort of miRs and
mirtrons that are susceptible to epigenetic silencing in
cancer. We have shown the presence of CpG hypermethy-
lation for many of these in UCC and found that certain
CpG shore alterations appear more disease specific than for
the corresponding island.
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